For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...
Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price ... about the company’s R&D strategy, which Walmsley has left in the hands of Hal Barron, who made his name at ...
Hosted on MSN14d
GSK could double CEO Emma Walmsley’s pay to $27 million in bid to bring U.K. exec salaries in line with the U.S.GSK could double its long-serving CEO Emma Walmsley’s pay packet to £21.6 million ($27.2 million) after admitting its boss's current pay didn’t reward her performance and would put off future ...
Five years into her transformation-focused tenure, Walmsley says the global drugmaker is at last ready to deliver results. She completed the final step of that overhaul this summer, spinning off ...
Bloomberg on MSN9mon
GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive ...
CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights the U.K. pharmaceutical company's refocused R&D strategy, with investments concentrated in the U.K., U.S ...
Emma Walmsley, CEO of GSK, is nearly eight years into her effort to return the British pharma company to growth, and her work is starting to pay off. Much credit goes to Arexvy, GSK’s first-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback